Contributions
Abstract: P644
Type: Poster Sessions
Abstract Category: Therapy - Others
Background: People with Multiple Sclerosis commonly report fatigue, which can vary in degree. Fatigue in PwMS has been related to physical disability, depression, medication and sleep disorders. Polysomnography (PSG) can identify unrecognized sleep disordered breathing (SDB) and quantify the degree of SDB in PwMS. Disease modifying therapies (DMT) are prescribed in an attempt to reduce disease activity/progression without adding to disease burden. Many factors (route, frequency, efficacy) determine choice of DMT, but the relationship of specific DMT to the presence/degree of fatigue potentially due to SDB is not well described. DMT choice should also take this factor into account.
Objective: To compare PSG documented sleep parameters in both Interferon and Copaxone treated PwMS who reported fatigue to identify if different sleep architecture is observed in groups utilizing different DMT.
Methods: Retrospective cross-sectional analysis of PwMS who reported fatigue, were not diagnosed with SDB and agreed to overnight PSG study. Patients reported DMT at time of PSG study.
Results: 130 PwMS (46.53±9.748 years, 72% female). Abnormalities in sleep architecture (SA) were common in both Interferon (n=86) and Copaxone (n=44) treated PwMS. PwMS SA DMT Copaxone was significantly different from PWMS SA Interferon regarding two sleep parameters: sleep latency (minutes) (p=0.035) and REM latency (minutes) (p=0.021184). 52% of PwMS DMT Copaxone had normal sleep latency (< 30 minutes), while 44% of PwMS DMT Interferons had normal sleep latency. 13% (n=11) of PwMS DMT interferon did not achieve REM sleep; of those who did (n=72), 10% had normal REM latency (REM-L) (80-110 minutes), 21% were below normal, 22% had REM-L 110-180 minutes, and 47% had REM-L >180 minutes. 7% (n=3) of PwMS DMT Copaxone never achieved REM sleep; of those who did (n=38), 21% had a normal REM-L (80-110 minutes), 21% REM-L < 80 minutes, 32% had REM-L 110-180 minutes, and 26% had REM-L >180.
Conclusions: Fatigue in PwMS is not only multifactorial, but DMT type might contribute to altered SA and fatigue reported. A higher percentage of PwMS DMT Copaxone had normal sleep latency than PwMS DMT interferons. PwMS treated with interferons were likely to have a greater prolonged REM latency compared to PwMS DMT Copaxone, especially in the REM latency >180 range. Further investigation into the relationship of how DMT choice might impact sleep architecture might impact treatment choice is needed.
Disclosure: (This study was supported by TEVA)
MG- Research support (Biogen, EMD Serono, Novartis, Sanofi, Teva); speaker fees/consultant (Acorda, Amgen, Biogen, EMD Serono, Medtronic, Novartis, Sanofi, Saol Therapeutics, Teva).
JS- Nothing to disclose
AG- Nothing to disclose
MZ- Speaker fees (Acorda, Biogen, Genzyme and Teva)
BB- Speaker fees (Biogen, Genotech, Genzyme and Teva).
MB: Nothing to disclose
LF- Nothing to disclose
Abstract: P644
Type: Poster Sessions
Abstract Category: Therapy - Others
Background: People with Multiple Sclerosis commonly report fatigue, which can vary in degree. Fatigue in PwMS has been related to physical disability, depression, medication and sleep disorders. Polysomnography (PSG) can identify unrecognized sleep disordered breathing (SDB) and quantify the degree of SDB in PwMS. Disease modifying therapies (DMT) are prescribed in an attempt to reduce disease activity/progression without adding to disease burden. Many factors (route, frequency, efficacy) determine choice of DMT, but the relationship of specific DMT to the presence/degree of fatigue potentially due to SDB is not well described. DMT choice should also take this factor into account.
Objective: To compare PSG documented sleep parameters in both Interferon and Copaxone treated PwMS who reported fatigue to identify if different sleep architecture is observed in groups utilizing different DMT.
Methods: Retrospective cross-sectional analysis of PwMS who reported fatigue, were not diagnosed with SDB and agreed to overnight PSG study. Patients reported DMT at time of PSG study.
Results: 130 PwMS (46.53±9.748 years, 72% female). Abnormalities in sleep architecture (SA) were common in both Interferon (n=86) and Copaxone (n=44) treated PwMS. PwMS SA DMT Copaxone was significantly different from PWMS SA Interferon regarding two sleep parameters: sleep latency (minutes) (p=0.035) and REM latency (minutes) (p=0.021184). 52% of PwMS DMT Copaxone had normal sleep latency (< 30 minutes), while 44% of PwMS DMT Interferons had normal sleep latency. 13% (n=11) of PwMS DMT interferon did not achieve REM sleep; of those who did (n=72), 10% had normal REM latency (REM-L) (80-110 minutes), 21% were below normal, 22% had REM-L 110-180 minutes, and 47% had REM-L >180 minutes. 7% (n=3) of PwMS DMT Copaxone never achieved REM sleep; of those who did (n=38), 21% had a normal REM-L (80-110 minutes), 21% REM-L < 80 minutes, 32% had REM-L 110-180 minutes, and 26% had REM-L >180.
Conclusions: Fatigue in PwMS is not only multifactorial, but DMT type might contribute to altered SA and fatigue reported. A higher percentage of PwMS DMT Copaxone had normal sleep latency than PwMS DMT interferons. PwMS treated with interferons were likely to have a greater prolonged REM latency compared to PwMS DMT Copaxone, especially in the REM latency >180 range. Further investigation into the relationship of how DMT choice might impact sleep architecture might impact treatment choice is needed.
Disclosure: (This study was supported by TEVA)
MG- Research support (Biogen, EMD Serono, Novartis, Sanofi, Teva); speaker fees/consultant (Acorda, Amgen, Biogen, EMD Serono, Medtronic, Novartis, Sanofi, Saol Therapeutics, Teva).
JS- Nothing to disclose
AG- Nothing to disclose
MZ- Speaker fees (Acorda, Biogen, Genzyme and Teva)
BB- Speaker fees (Biogen, Genotech, Genzyme and Teva).
MB: Nothing to disclose
LF- Nothing to disclose